Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ASK: "THE LAST DON" OF MOMENTUM TRADES -- Ignore unavailable to you. Want to Upgrade?

To: P.E. Allen who wrote (12168)	4/20/1999 11:59:00 AM
From: Due Diligence	Respond to of 15987

OKTI news: (PR Wires) DJ: Oxford-Knight Signs Letter of Intent to Acquire a 20% In DJ: Oxford-Knight Signs Letter of Intent to Acquire a 20% Interest in Medical Technology Company GRAND ISLAND, N.Y., April 20 /PRNewswire/ -- Oxford-Knight International, Inc, (OTC Bulletin Board: OKTI) announced today that it has signed a letter of intent to acquire 20% of Diagnostic Technology Corporation of Jenkintown, Pa. Diagnostic Technology is a medical technology company that has developed an innovative hand-held instrument which in two minutes has the ability to perform blood chemistry analysis. The major advantages of this particular instrument is its portability, speed, ease of use, and its affordability to the medical community. It is the intent of this acquistion, to spin off 20% of Diagnostic as a new publicly traded company and have OKTI shareholders receive proceeds via stock in the new venture based upon a record date disclosed in the future. It is estimated that it will take 3 weeks for the completion of the acquisition once all due diligence has been completed by OKTI's management and legal counsel. "This is a major step for our company and its shareholders," stated Paul Syracuse, Oxford Knight's President and CEO. The device in question, once approved by the FDA via the 510K rule (approximately 90-120 days), would be a highly valuable asset for the company and ultimately a major advance in the clinical testing sector of the medical industry. Oxford-Knight International, Inc. plans to specialize in mergers & acquistions, leveraged buy-outs, business consulting, real estate development, construction (residential and commercial), assisted living facilities (new), and retail & wholesale distribution of auto accessories. The company has 2.282 million shares outstanding. For more information on Oxford-Knight, contact Jeff Brommer, Investor Relations at 800-749-0114. This release contains forward-looking statements, with respect to the results of operations and business of Oxford-Knight International, Inc. that involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. Risks and uncertainties of the Company will be detailed from time to time in the Company's periodic reports. The Company intends that such about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "safe harbors" provision of the Private Securities Litigation Reform Act of 1995. Investments 101, Ltd. has been retained by Oxford-Knight to provide investor relations services for a period of three months beginning April 9, 1999. Investments 101, Ltd. is being compensated for services rendered, with 150,000 shares of free-trading common stock. Jeff Brommer, his family, friends, and associates may from time to time buy and sell the above mentioned security in the open market. /CONTACT: Jeff Brommer of Investments 101, Ltd., 800-749-0114/ 10:03 EDT * end of story *